–
Статьи в журналах
-
- 2025 Аnalyses on impact of tumor burden at progression and changes in IMDC from baseline in patients (pts) with advanced renal cell carcinoma (ARCC) treated with lenvatinib + pembrolizumab (l+P) in the phase 3 CLEAR trial
- Grünwald V., Keizman D., Bedke J., Staehler M.D., Matveev V.B., George S., Hutson T.E., Vaishampayan U.N., Merchan Ja R., Eto M., Rha S.Y., Waddell T., Sabbatini R., Barthelemy Ph, Burgents J.E., Ren M., Ia Brown, Saal H., Choueiri T.K., Motzer R.J.
- в журнале Journal of Clinical Oncology, издательство American Society of Clinical Oncology (United States), том 43, № 5, с. 531-10
-
- 2024 Lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in advanced renal cell carcinoma (aRCC): Patterns of progression and subsequent therapy in the CLEAR trial
- Grünwald Viktor, Motzer Robert J., Keizman Daniel, Bedke Jens, Schmidinger Manuela, Staehler Michael D., Matveev Vsevolod B., George Saby, Hutson Thomas E., Vaishampayan Ulka N., Merchan Jaime R., Eto Masatoshi, Rha Sun Young, Waddell Tom, Sabbatini Roberto, Barthelemy Philippe, Burgents Joseph E., Ren Min, Brown Ian, CHOUEIRI Toni K.
- в журнале Journal of Clinical Oncology, издательство American Society of Clinical Oncology (United States), том 42, № 16_suppl, с. 4524-4524 DOI